Brain serotonergic circuitries;Circuitos serotoninérgicos cerebrales

Dialogues in Clinical Neuroscience

Volumn 12, Issue 4, 2010, Pages 471-487

  Charnay, Yves ^a   Léger, Lucienne ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

5 hydroxytryptamine; Human brain; In vivo imaging; Neuroanatomy; Raphe nucleus; Serotonin receptor

Indexed keywords

SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN;

ARTICLE; BINDING AFFINITY; BRAIN FUNCTION; BRAIN REGION; CELL STRUCTURE; CENTRAL NERVOUS SYSTEM; HUMAN; IN VIVO STUDY; NEUROANATOMY; NEUROCHEMISTRY; NEUROTRANSMISSION; PERIKARYON; RECEPTOR BINDING; SEROTONIN BRAIN LEVEL; ANIMAL; BRAIN; HISTOLOGY; METABOLISM; NERVE CELL NETWORK; NERVE TRACT;

ANIMALS; BRAIN; HUMANS; NERVE NET; NEURAL PATHWAYS; NEUROANATOMY; NEUROCHEMISTRY; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 79952477036     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (183)

1. Barbas D, DesGroseillers L, Castellucci VF, Carew TJ, Marinesco S. Multiple serotonergic mechanisms contributing to sensitization in aplysia: evidence of diverse serotonin receptor subtypes. Learn Mem. 2003;10:373-386.
2. Chase DL, Koelle MR. Biogenic amine neurotransmitters in C. elegans. WormBook. 2007:1-15.
3. Erspamer V. Presenza di enteramina o di una sostanza enteraminosimile negli estratti gastrointestinali e splenici dei pesci e negli estratti gastroenterici delle ascidie. Experientia. 1946;11:369-371.
4. Mathias AP, Ross DM, Schachter M. Identification and distribution of 5-hydroxytryptamine in a sea anemone. Nature. 1957;180:658-
5. Ishihara A, Hashimoto Y, Tanaka C, et al. The tryptophan pathway is involved in the defense responses of rice against pathogenic infection via serotonin production. Plant J. 2008;54:481-495.
6. Murch SJ, Alan AR, Cao J, Saxena PK. Melatonin and serotonin in flowers and fruits of Datura metel L. J Pineal Res. 2009;47:277-283.
7. Dalgliesh CE, Toh CC, Work TS. Fractionation of the smooth muscle stimulants present in extracts of gastro-intestinal tract. Identification of 5-hydroxytryptamine and its distinction from substance P. J Physiol. 1953;120:298-310.
8. Erspamer V. Pharmakologische studien über enteramin: Über die, wirkung von acetonextrkten der kaninchenmagenschleimhaut auf den blutdruck und auf isoliert überlebende organe. Arch Exp Path Pharmakol. 1940;196:343-407.
9. Euler Von US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol. 1931;72:74-87.
10. Rapport MM, Green AA, Page IH. Crystalline serotonin. Science. 1948;108:329-230.
11. Brodie, BB, Pletscher A, Shore PA. Evidence that serotonin has a role in brain function. Science. 1955;122:968.
12. Amin AH, Crawford TB, Gaddum JH. The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog. J Physiol. 1954;126:596-618.
13. Twarog BM, Page IH. Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol. 1953;175:157-161.
14. Schneider JA, Yonkman FF. Action of serotonin (5-hydroxytryptamine) on vagal afferent impulses in the cat. Am J Physiol. 1953;174:127-134.
15. Douglas WW, Toh CC. The respiratory stimulant action of 5-hydroxytryptamine (serotonin) in the dog. J Physiol. 1953;120:311-318.
16. Herlenius E, Lagercrantz H. Neurotransmitters and neuromodulators during early human development. Early Hum Dev. 2001;65:21-37.
17. Sundstrom E, Kolare S, Souverbie, F, et al. Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. Brain Res Dev Brain Res. 1993;75:1-12.
18. Garvin B, Wiley JW. The role of serotonin in irritable bowel syndrome: implications for management. Curr Gastroenterol Rep. 2008;10:363-368.
19. Jhoo JH, Yoon IY, Kim YK, et al. Availability of brain serotonin transporters in patients with restless legs syndrome. Neurology. 2010;74:513-518.
20. Kinney HC, Richerson GB, Dymecki SM, Darnall RA, Nattie, EE. The brainstem and serotonin in the sudden infant death syndrome. Annu Rev Pathol. 2009;4:517-550.
21. Duncan JR, Paterson DS, Hoffman JM, et al. Brainstem serotonergic deficiency in sudden infant death syndrome. JAMA. 2010;303:430-437.
22. Wassink TH, Hazlett HC, Epping EA, et al. Cerebral cortical gray matter overgrowth and functional variation of the serotonin transporter gene in autism. Arch Gen Psychiatry. 2007;64:709-717.
23. Goadsby PJ. Serotonin receptor ligands: treatments of acute migraine and cluster headache. Handb Exp Pharmacol. 2007:129-143.
24. Jindal RD. Insomnia in patients with depression: some pathophysiological and treatment considerations. CNS Drugs. 2009;23:309-329.
25. Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry. 2009;66:627-635.
26. Nemeroff CB, Owens MJ. The role of serotonin in the pathophysiology of depression: as important as ever. Clin Chem. 2009;55:1578-1579.
27. Jean A, Conductier G, Manrique C, et al. Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens. Proc Natl Acad Sci U S A. 2007;104:16335-16340.
28. Kaye WH, Frank GK, Bailer UF, et al. Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiol Behav. 2005;85:73-81.
29. Rasmussen H, Erritzoe D, Andersen R, et al. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with firstepisode schizophrenia. Arch Gen Psychiatry. 2010;67:9-16.
30. Azmitia EC, Nixon R. Dystrophic serotonergic axons in neurodegenerative diseases. Brain Res. 2008;1217:185-194.
31. Newhouse P, Tatro A, Naylor M, Quealey K, Delgado P. Alzheimer disease, serotonin systems, and tryptophan depletion. Am J Geriatr Psychiatry. 2002;10:483-484.
32. Ouchi Y, Yoshikawa E, Futatsubashi M, Yagi S, Ueki T, Nakamura K. Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. J Nucl Med. 2009;50:1260-1266.
33. Hamon M, Bourgoin S. Pharmacological profile of antidepressants: a likely basis for their efficacity and side effects. Eur Neuropsychopharmacol. 2006;16:S625-S632.
34. Racagni G, Popoli M. The pharmacological properties of antidepressants. Int Clin Psychopharmacol. 2010;25:117-131.
35. Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006;3:CD006115.
36. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115-124.
37. Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev. 2010;4:CD008042.
38. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008;172:199-212.
39. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008;172:177-197.
40. Theisen FM, Haberhausen M, Firnges MA, et al. No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007;7:275-281.
41. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology. 1999;21(2 suppl):16S-23S.
42. Gonzalez-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439-452.
43. Kish SJ, Fitzmaurice PS, Boileau I, et al. Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl). 2009;202:649-661.
44. Sitte HH, Freissmuth M. The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters--why amphetamines take two to tango. J Neurochem. 2010;112:340-355.
45. Sucic S, Dallinger S, Zdrazil B, et al. The N terminus of monoamine transporters is a lever required for the action of amphetamines. J Biol Chem. 2010;285:10924-10938.
46. Lesurtel M, Soll C, Graf R, Clavien PA. Role of serotonin in the hepatogastroIntestinal tract: an old molecule for new perspectives. Cell Mol Life Sci. 2008;65:940-952.
47. Bertrand PP, Bertrand RL. Serotonin release and uptake in the gastrointestinal tract. Auton Neurosci. 2010;153:47-57.
48. Descarries L, Beaudet A, Watkins KC. Serotonin nerve terminals in adult rat neocortex. Brain Res. 1975;100:563-588.
49. Hoffman BJ, Hansson SR, Mezey E, Palkovits M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol. 1998;19:187-231.
50. Agnati LF, Guidolin D, Guescini M, Genedani S, Fuxe K. Understanding wiring and volume transmission. Brain Res Rev. 2010;64:137-159.
51. Descarries L, Mechan A. Ultrastructural evidence for diffuse transmission by monoamine and acetylcholine neurones of the central nervous system. Prog Brain Res. 2000;125:27-47.
52. Umbriaco D, Garcia S, Beaulieu C, Descarries L. Relational features of acetylcholine, noradrenaline, serotonin and GABA axon terminals in the stratum radiatum of adult rat hippocampus (CA1). Hippocampus. 1995;5:605-620.
53. Silber BY, Schmitt JA. Effects of tryptophan loading on human cognition, mood, and sleep. Neurosci Biobehav Rev. 2010;34:387-407.
54. Daly E, Deeley Q, Hallahan B, et al. Effects of acute tryptophan depletion on neural processing of facial expressions of emotion in humans. Psychopharmacology (Berl). 2010;210:499-510.
55. Mendelsohn D, Riedel WJ, Sambeth A. Effects of acute tryptophan depletion on memory, attention and executive functions: a systematic review. Neurosci Biobehav Rev. 2009;33:926-952.
56. Moreno FA, Parkinson D, Palmer C, et al. CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. Eur Neuropsychopharmacol. 2010;20:18-24.
57. Matthes S, Mosienko V, Bashammakh S, Alenina N, Bader M. Tryptophan hydroxylase as novel target for the treatment of depressive disorders. Pharmacology. 2010;85:95-109.
58. Choi KY, Yoon HK, Kim YK. Association between serotonin-related polymorphisms in 5HT2A, TPH1, TPH2 genes and bipolar disorder in Korean population. Psychiatry Investig. 2010;7:60-67.
59. Magnay JL, Ismail KM, Chapman G, Cioni L, Jones PW, O'Brien S. Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder. Am J Obstet Gynecol. 2006;195:1254-1259.
60. Mergen H, Demirel B, Akar T, Senol E. Lack of association between the serotonin transporter and tryptophan hydroxylase gene polymorphisms and completed suicide. Psychiatr Genet. 2006;16:53.
61. Zhang X, Beaulieu JM, Gainetdinov RR, Caron MG. Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. Cell Mol Life Sci. 2006;63:6-11.
62. Saetre P, Lundmark P, Wang A, et al. The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: a multicentre case-control study and meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:387-396.
63. Galfalvy H, Huang YY, Oquendo MA, Currier D, Mann JJ. Increased risk of suicide attempt in mood disorders and TPH1 genotype. J Affect Disord. 2009;115:331-338.
64. Manegold C, Hoffmann GF, Degen I, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis. 2009;32:371-380.
65. Sirek A, Sirek OV. Serotonin: a review. Can Med Assoc J. 1970;102:846-849.
66. Nakatani Y, Sato-Suzuki I, Tsujino N, et al. Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur J Neurosci. 2008;27:2466-2472.
67. Coccaro EF, Lee R, Kavoussi RJ. Inverse relationship between numbers of 5-HT transporter binding sites and life history of aggression and intermittent explosive disorder. J Psychiatr Res. 2010;44:137-142.
68. Coccaro EF, Lee R. Cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid: reciprocal relationships with impulsive aggression in human subjects. J Neural Transm. 2010;117:241-248.
69. Asellus P, Nordstrom P, Jokinen J. Cholesterol and CSF 5-HIAA in attempted suicide. J Affect Disord. 2010;125:388-392.
70. Jokinen J, Nordstrom AL, Nordstrom P. Cholesterol, CSF 5-HIAA, violence and intent in suicidal men. Psychiatry Res. 2010;178:217-219.
71. Wallner B, Machatschke IH. The evolution of violence in men: the function of central cholesterol and serotonin. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:391-397.
72. Hardisty RM, Stacey RS. 5-Hydroxytryptamine in normal human platelets. J Physiol. 1955;130:711-720.
73. Leger L, Mouren-Mathieu AM, Descarries L. [Radioautographic identification of central monoaminergic neurons by local micro-instillation of tritiated serotonin or noradrenaline in cats]. C R Acad Sci Hebd Seances Acad Sci D. 1978;286:1523-1526.
74. Lichtensteiger W, Langemann H. The uptake of serotonin by central neurons normally containing catecholamines. Adv Pharmacol. 1968;6(Pt A):123.
75. Von Wartburg JP. Uptake of 5-hydroxytryptophan-3-C14 and its metabolism in rat brain cortex slices. Can J Biochem Physiol. 1962;40:1439-1448.
76. Apparsundaram S, Stockdale DJ, Henningsen RA, Milla ME, Martin RS. Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism. J Pharmacol Exp Ther. 2008;327:982-990.
77. Steiner JA, Carneiro AM, Wright J, et al. cGMP-dependent protein kinase Ialpha associates with the antidepressant-sensitive serotonin transporter and dictates rapid modulation of serotonin uptake. Mol Brain. 2009;2:26.
78. Ramamoorthy S, Bauman AL, Moore KR, et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1993;90:2542-2546.
79. Hoffman BJ, Mezey E, Brownstein MJ. Cloning of a serotonin transporter affected by antidepressants. Science. 1991;254:579-580.
80. Demchyshyn LL, Pristupa ZB, Sugamori KS, et al. Cloning, expression, and localization of a chloride-facilitated, cocaine-sensitive serotonin transporter from Drosophila melanogaster. Proc Natl Acad Sci U S A. 1994;91:5158-5162.
81. Amilhon B, Lepicard E, Renoir T, et al. VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety. J Neurosci. 2010;30:2198-210.
82. Austin MC, Bradley CC, Mann JJ, Blakely RD. Expression of serotonin transporter messenger RNA in the human brain. J Neurochem. 1994;62:2362-2367.
83. Harro J, Merenakk L, Nordquist N, Konstabel K, Comasco E, Oreland L. Personality and the serotonin transporter gene: Associations in a longitudinal population-based study. Biol Psychol. 2009;81:9-13.
84. Nordquist N, Oreland L. Serotonin, genetic variability, behaviour, and psychiatric disorders--a review. Ups J Med Sci. 2010;115:2-10.
85. Marini S, Bagnoli S, Bessi V, et al. Implication of serotonin-transporter (5-HTT) gene polymorphism in subjective memory complaints and mild cognitive impairment (MCI). Arch Gerontol Geriatr. 2010. In press.
86. Steiner JA, Carneiro AM, Blakely RD. Going with the flow: trafficking dependent and -independent regulation of serotonin transport. Traffic. 2008;9:1393-1402.
87. Willeit M, Praschak-Rieder N. Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: a review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. Neuroimage. 2010;53:878-892.
88. Hendricks TJ, Fyodorov DV, Wegman LJ, et al. Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. Neuron. 2003;37:233-247.
89. Kriegebaum CB, Gutknecht L, Bartke L, et al. The expression of the transcription factor FEV in adult human brain and its association with affective disorders. J Neural Transm. 2010;117:831-836.
90. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science. 2010;329:1537-1541.
91. Zhang YW, Gesmonde J, Ramamoorthy S, Rudnick G. Serotonin transporter phosphorylation by cGMP-dependent protein kinase is altered by a mutation associated with obsessive compulsive disorder. J Neurosci. 2007;27:10878-10886.
92. Christiansen L, Tan Q, Iachina M, et al. Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population. Biol Psychiatry. 2007;61:223-230.
93. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B. Gain-offunction haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet. 2006;15:299-305.
94. Lin Z, Walther D, Yu XY, Li S, Drgon T, Uhl GR. SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet. 2005;14:1393-1404.
95. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol Chemother. 1957;12:323-328.
96. Peroutka SJ, Snyder SH. Two distinct serotonin receptors: regional variations in receptor binding in mammalian brain. Brain Res. 1981;208:339-347.
97. Gothert M, Schlicker E. Classification of serotonin receptors. J Cardiovasc Pharmacol. 1987;10(suppl 3):S3-S7.
98. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res. 2008;195:198-213.
99. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083-1152.
100. Fink KB, Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev. 2007;59:360-417.
101. Beattie, DT, Smith JA. Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:181-203.
102. Sanger GJ. 5-Hydroxytryptamine and the gastrointestinal tract: where next? Trends Pharmacol Sci. 2008;29:465-471.
103. Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT3 receptor--the relationship between structure and function. Neuropharmacology. 2009;56:273-284.
104. Holbrook JD, Gill CH, Zebda N, et al. Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem. 2009;108:384-396.
105. Bockaert J, Perroy J, Becamel C, Marin P, Fagni L. GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies. Annu Rev Pharmacol Toxicol. 2010;50:89-109.
106. Millan MJ, Marin P, Bockaert J, la Cour CM. Signaling at G-proteincoupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci. 2008;29:454-464.
107. Varin T, Saettel N, Villain J, et al. 3D Pharmacophore, hierarchical methods, and 5-HT4 receptor binding data. J Enzyme Inhib Med Chem. 2008;23:593-603.
108. Bhattacharyya S, Puri S, Miledi R, Panicker MM. Internalization and recycling of 5-HT2A receptors activated by serotonin and protein kinase Cmediated mechanisms. Proc Natl Acad Sci U S A. 2002;99:14470-14475.
109. Idkowiak-Baldys J, Baldys A, Raymond JR, Hannun YA. Sustained receptor stimulation leads to sequestration of recycling endosomes in a classical protein kinase C- and phospholipase D-dependent manner. J Biol Chem. 2009;284:22322-22331.
110. Erritzoe D, Holst K, Frokjaer VG, et al. A nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: an in vivo molecular imaging study in humans. J Neurosci. 2010;30:3391-3397.
111. Corradi J, Gumilar F, Bouzat C. Single-channel kinetic analysis for activation and desensitization of homomeric 5-HTA receptors. Biophys J. 2009;97:1335-1345.
112. Gonzalez-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/ glutamate receptor complex implicated in psychosis. Nature. 2008;452:93-97.
113. Bruno A, Guadix AE, Costantino G. Molecular dynamics simulation of the heterodimeric mGluR2/5HT(2A) complex. An atomistic resolution study of a potential new target in psychiatric conditions. J Chem Inf Model. 2009;49:1602-1616.
114. Gonzalez-Maeso J. Anxious interactions. Nat Neurosci. 2010;13:524-526.
115. Magalhaes AC, Holmes KD, Dale LB, et al. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci. 2010;13:622-629.
116. Allen JA, Yadav PN, Roth BL. Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases. Neuropharmacology. 2008;55:961-968.
117. Zimmer L, Riad M, Rbah L, et al. Toward brain imaging of serotonin 5-HT1A autoreceptor internalization. Neuroimage. 2004;22:1421-1426.
118. Joyce D, Summerfield A. Effects of drugs related to serotonin on water intake and defecation in rats. Implications for behavioural studies. Arch Int Pharmacodyn Ther. 1966;161:489-494.
119. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res. 2003;37:357-373.
120. Steinbusch HWM. Distribution of serotonin-immunoreactivity in the central nervous system of the rat. Cell bodies and terminals. Neuroscience. 1981;6:557-618.
121. Leger L, Charnay Y, Hof PR, Bouras C, Cespuglio R. Anatomical distribution of serotonin-containing neurons and axons in the central nervous system of the cat. J Comp Neurol. 2001;433:157-182.
122. Azmitia EC, Gannon PJ. The primate serotonergic system: a review of human and animal studies and a report on Macaca fascicularis. Adv Neurol. 1986;43:407-468.
123. Nobin A, Bjorklund A. Topography of the monoamine neuron systems in the human brain as revealed in fetuses. Acta Physiol Scand Suppl. 1973;388:1-40.
124. Takahashi H, Nakashima S, Ohama E, Takeda S, Ikuta F. Distribution of serotonin-containing cell bodies in the brainstem of the human fetus determined with immunohistochemistry using antiserotonin serum. Brain Dev. 1986;8:355-365.
125. Baker KG, Halliday GM, Halasz P, et al. Cytoarchitecture of serotoninsynthesizing neurons in the pontine tegmentum of the human brain. Synapse. 1991;7:301-320.
126. Baker KG, Halliday GM, Hornung JP, Geffen LB, Cotton RG, Tork I. Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. Neuroscience. 1991;42:757-775.
127. Halliday GM, Li YW, Joh TH, et al. Distribution of monoamine-synthesizing neurons in the human medulla oblongata. J Comp Neurol. 1988;273:301-317.
128. Hornung JP. The human raphe nuclei and the serotonergic system. J Chem Neuroanat. 2003;26:331-343.
129. Nieuwenhuis R. Monoamines: Chemoarchitecture of the Brain. Berlin, Germany: Springer Verlag; 1985:33-41.
130. Kosofsky BE, Molliver ME. The serotoninergic innervation of cerebral cortex: different classes of axon terminals arise from dorsal and median raphe nuclei. Synapse. 1987;1:153-168.
131. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 1988;8:2788-2803.
132. Kojima M, Takeuchi Y, Goto M, Sano Y. Immunohistochemical study on the localization of serotonin fibers and terminals in the spinal cord of the monkey (Macaca fuscata). Cell Tissue Res. 1983;229:23-36.
133. Anderson IM, McKie, S, Elliott R, Williams SR, Deakin JF. Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology. 2008;55:1029-1037.
134. Freitas-Ferrari MC, Hallak JEC, Trzesniak C, et al. Neuroimaging in social anxiety disorder: a systematic review of the litterature. Progress Psychopharmacol Biol Psy. 2010;34:565-580.
135. Murphy SE. Using functional neuroimaging to investigate the mechanisms of action of selective serotonin reuptake inhibitors (SSRIs). Curr Pharm Des. 2010;16:1990-1997.
136. Huang Y, Zheng MQ, Gerdes JM. Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? Curr Top Med Chem. 2010;10:1499-1526.
137. Smith DF, Jakobsen S. Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol. 2009;19:611-628.
138. Gallezot JD, Nabulsi N, Neumeister A, et al. Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [C]P943 in humans. J Cereb Blood Flow Metab. 2010;30:196-210.
139. Marner L, Gillings N, Madsen K, et al. Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. Neuroimage. 2010;50:855-861.
140. Varnas K, Nyberg S, Halldin C, et al. Quantitative analysis of [C]AZ10419369 binding to 5-HT(1B) receptors in human brain. J Cereb Blood Flow Metab. 2010. In press.
141. Pike VW. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci. 2009;30:431-440.
142. Fink M, Wadsak W, Savli M, et al. Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. Neuroimage. 2009;45:598-605.
143. Witte AV, Floel A, Stein P, et al. Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects. Hum Brain Mapp. 2009;30:2558-2570.
144. Erritzoe D, Frokjaer VG, Haahr MT, et al. Cerebral serotonin transporter binding is inversely related to body mass index. Neuroimage. 2010;52:284-289.
145. Kupers R, Frokjaer VG, Naert A, et al. A PET [18F]altanserin study of 5-HT2A receptor binding in the human brain and responses to painful heat stimulation. Neuroimage. 2009;44:1001-1007.
146. Kish SJ, Lerch J, Furukawa Y, et al. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[ C]DASB and structural brain imaging study. Brain. 2010;133(Pt 6):1779-1797.
147. Borg J. Molecular imaging of the 5-HT(1A) receptor in relation to human cognition. Behav Brain Res. 2008;195:103-111.
148. Fakra E, Hyde LW, Gorka A, et al. Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. Arch Gen Psychiatry. 2009;66:33-40.
149. Hariri AR, Drabant EM, Weinberger DR. Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol Psychiatry. 2006;59:888-897.
150. Munafo MR, Brown SM, Hariri AR. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry. 2008;63:852-857.
151. Yoshida M, Takayanagi Y, Inoue K, et al. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci. 2009;29:2259-2271.
152. Di Giovanni G, Esposito E, Di Matteo V. Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther. 2010;16:179-194.
153. Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog Brain Res. 2008;172:423-463.
154. Haj-Dahmane S, Shen RY. Endocannabinoids suppress excitatory synaptic transmission to dorsal raphe serotonin neurons through the activation of presynaptic CB1 receptors. J Pharmacol Exp Ther. 2009;331:186-196.
155. Monti JM. The structure of the dorsal raphe nucleus and its relevance to the regulation of sleep and wakefulness. Sleep Med Rev. 2010;14:319-327.
156. Zoli M, Jansson A, Sykova E, Agnati LF, Fuxe K. Volume transmission in the CNS and its relevance for neuropsychopharmacology. Trends Pharmacol Sci. 1999;20:142-150.
157. Griessenauer CJ, Chang SY, Tye SJ, et al. Wireless Instantaneous Neurotransmitter Concentration System: electrochemical monitoring of serotonin using fast-scan cyclic voltammetry-a proof-of-principle study. J Neurosurg. 2010;113:656-665.
158. Pessoa L. Emotion and cognition and the amygdala: from "what is it?" to "what's to be done?". Neuropsychologia. 2010;48:3416-3429.
159. Smith GS, Kramer E, Hermann C, et al. Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biol Psychiatry. 2009;66:259-266.
160. Fisher PM, Meltzer CC, Price JC, et al. Medial prefrontal cortex 5-HT(2A) density is correlated with amygdala reactivity, response habituation, and functional coupling. Cereb Cortex. 2009;19:2499-2507.
161. Hariri AR, Holmes A. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn Sci. 2006;10:182-191.
162. Michelsen KA, Prickaerts J, Steinbusch HW. The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease. Prog Brain Res. 2008;172:233-264.
163. Monti JM. The role of dorsal raphe nucleus serotonergic and nonserotonergic neurons, and of their receptors, in regulating waking and rapid eye movement (REM) sleep. Sleep Med Rev. 2010;14:319-327.
164. Lanfumey L, Mongeau R, Cohen-Salmon C, Hamon M. Corticosteroidserotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci Biobehav Rev. 2008;32:1174-1184.
165. Moser U, Wadsak W, Spindelegger C, et al. Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulfate in healthy women. Neurosci Lett. 2010;476:161-165.
166. Zheng P. Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance. Prog Neurobiol. 2009;89:134-152.
167. Bjork K, Sjogren B, Svenningsson P. Regulation of serotonin receptor function in the nervous system by lipid rafts and adaptor proteins. Exp Cell Res. 2010;316:1351-1356.
168. Benmansour S, Deltheil T, Piotrowski J, et al. Influence of brainderived neurotrophic factor (BDNF) on serotonin neurotransmission in the hippocampus of adult rodents. Eur J Pharmacol. 2008;587:90-98.
169. Savelieva KV, Zhao S, Pogorelov VM, et al. Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants. PLoS One. 2008;3:e3301.
170. Herzog H, Pietrzyk U, Shah NJ, Ziemons K. The current state, challenges and perspectives of MR-PET. Neuroimage. 49:2072-2082.
171. King MV, Marsden CA, Fone KC. A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci. 2008;29:482-492.
172. Mostany R, Pazos A, Castro ME. Autoradiographic characterisation of [35S]GTPgammaS binding stimulation mediated by 5-HT1B receptor in postmortem human brain. Neuropharmacology. 2005;48:25-33.
173. Varnas K, Hall H, Bonaventure P, Sedvall G. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [H]GR 125743. Brain Res. 2001;915:47-57.
174. Bai F, Yin T, Johnstone EM, et al. Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004;484:127-139.
175. Lucaites VL, Krushinski JH, Schaus JM, Audia JE, Nelson DL. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:178-184.
176. Meyer PT, Bhagwagar Z, Cowen PJ, Cunningham VJ, Grasby PM, Hinz R. Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses. Neuroimage. 2010;50:984-993.
177. Bonhaus DW, Bach C, DeSouza A, et al. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol. 1995;115:622-628.
178. Giorgetti M, Tecott LH. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol. 2004;488:1-9.
179. Varnas K, Halldin C, Pike VW, Hall H. Distribution of 5-HT4 receptors in the postmortem human brain--an autoradiographic study using [125I]SB 207710. Eur Neuropsychopharmacol. 2003;13:228-234.
180. Lucas G, Rymar VV, Du J, et al. Serotonin 4 (5-HT4) receptor agonists are putative antidepressants with a rapid onset of action. Neuron. 2007;55:712-725.
181. Thomas DR. 5-ht5A receptors as a therapeutic target. Pharmacol Ther. 2006;111:707-714.
182. Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics. 2008;5:458-469.
183. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl). 2009;206:345-354.